Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03442751 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
A Phase 3 study, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 201
- Enrollment target
NCT03442751 is a Phase 3 study that has completed, run by Glaukos Corporation. The registered enrollment target is 201 participants.
The verdict
NCT03442751, a Phase 3 study, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 201 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus. Epithelium-on CXL uses a formulation that allows the riboflavin to penetrate the cornea without the need to remove the epithelium, the outer most layer of the cornea.
Interventions
- DRUG Placebo
- DRUG Test Article A
- DRUG Test Article B
- DEVICE KXL medical device system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2018-04-06 |
| Est. Completion | 2020-08-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03442751
The ClinicalTrials.gov registry entry for NCT03442751 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03442751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03442751 about?
NCT03442751 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus". To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus. Epithelium-on CXL uses a formulation that allows the riboflavin to penetrate the cornea without the...
What is the current status of trial NCT03442751?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 201 participants. The study started on 2018-04-06. Estimated completion is 2020-08-10.
What interventions are being tested in trial NCT03442751?
The interventions under investigation include: Placebo (DRUG), Test Article A (DRUG), Test Article B (DRUG), KXL medical device system (DEVICE).
Who is sponsoring clinical trial NCT03442751?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.